Immunomodulatory Drugs Revlimid (lenalidomide) And CC-4047 ...

Trang chủ » Cc-5013-nhl-008 » Immunomodulatory Drugs Revlimid (lenalidomide) And CC-4047 ...

Có thể bạn quan tâm

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content Dot gov

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation pubmed logo Search: Search Advanced Clipboard User Guide Save Email Send to
  • Clipboard
  • My Bibliography
  • Collections
  • Citation manager
Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Subject: 1 selected item: 18392823 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

  • Create a new collection
  • Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

  • My Bibliography
Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons
  • Yes
  • No
Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Full text links

full text provider logo Springer Free PMC article Full text links

Actions

CiteCollectionsAdd to Collections
  • Create a new collection
  • Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel Display options Display options Format AbstractPubMedPMID

Share

  • Permalink Copy

Page navigation

  • Title & authors
  • Abstract
  • Figures
  • Similar articles
  • Cited by
  • References
  • MeSH terms
  • Substances
  • Related information
  • LinkOut - more resources
Title & authors Abstract Figures Similar articles Cited by References MeSH terms Substances Related information LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Revlimid (Lenalidomide, CC-5013) and CC-4047 are IMiDs immunomodulatory drugs that have been described as having immunomodulatory properties and anti-tumor activity. Here we report proapoptotic effects of CC-5013 and CC-4047 on tumor cells in a co-culture model of PBMC and tumor cells. CC-5013 and CC-4047 enhanced PBMC activity leading to tumor cell apoptosis in K562/PBMC co-culture model. We also demonstrate that the natural killer (NK) cell population of PBMC was essential in inducing K562 apoptosis. Increases of NK and natural killer T (NKT) cell populations by CC-5013 and CC-4047 was observed along with modulation of NK cell CD56 adhesion marker. In addition, our data indicate that NK activation by CC-4047 was dependent on other cell types of PBMC. We expanded the application of K562/PBMC co-culture model to other hematological and solid tumors. In Raji/PBMC co-culture model, CC-5013 and CC-4047 dose-dependently augmented tumor cell apoptosis. Pre-treatment of Raji cells with Rituximab further enhanced apoptosis induced by CC-5013 or CC-4047-treated PBMC. Moreover, CC-5013 and CC-4047 significantly increased PC-3 prostate cancer cell apoptosis in PC-3/PBMC co-culture, either as single agent or in combination with Docetaxel. Together, the results reveal that co-culture models are suitable cellular systems to assess anti-tumor activities of these compounds. Our findings support clinical evaluation of CC-5013 and CC-4047 in relapsed NHL with Rituximab and in prostate cancer with Docetaxel.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

CC-4047 enhances PBMC activity in…

Fig. 1

CC-4047 enhances PBMC activity in inducing K562 apoptosis with or without IL-2 pretreatment.…

Fig. 1 CC-4047 enhances PBMC activity in inducing K562 apoptosis with or without IL-2 pretreatment. a PBMC were treated with or without 20 units/ml of IL-2 for 72 h followed by 10 μM CC-4047 for 72 h. K562 cells were labeled with PKH26 dye prior to co-culture with PBMC at 15:1 effector-to-target ratio. After co-culture, the mixture of K562 cells and PBMC was labeled with Annexin V-FITC. This experiment was performed with PBMC from three different donors. Representative density plots of K562/PBMC co-culture with or without CC-4047 treatment are shown here. K562 cells can be distinguished from PBMC by gating PKH26 positive population (y-axis). Double positive cell population represents apoptotic K562 cells as shown in the upper right-hand box of each plot. CC-4047 increased apoptosis of K562 cells to 61.9% (no IL-2) or 80.1% (with IL-2) compared to DMSO-treated groups (22.1 or 59.5%, respectively). b CC-4047 enhances PBMC-mediated apoptosis of K562 cells at various effector-to-target ratios with or without IL-2 treatment. PBMC pretreated with CC-4047 were mixed with K562 cells at the indicated effector-to-target ratios for 3 h. Cells were then analyzed as described in Materials and methods. Results shown are representative of three independent experiments with different PBMC donors
Fig. 2

Fig. 2

CC-4047 and CC-5013 increase PBMC-mediated…

Fig. 2

CC-4047 and CC-5013 increase PBMC-mediated apoptosis of K562 cells in the absence of…

Fig. 2 CC-4047 and CC-5013 increase PBMC-mediated apoptosis of K562 cells in the absence of IL-2. Various doses of CC-4047 and CC-5013 were evaluated in the co-culture model without IL-2 pretreatment of PBMC. Fold increase in K562 apoptosis in CC-4047 and CC-5013 treated group versus DMSO treated group was calculated. Results shown are mean fold increase of apoptosis (±SD) from three independent experiments using different PBMC donors
Fig. 3

Fig. 3

NK cells play important roles…

Fig. 3

NK cells play important roles in inducing K562 apoptosis enhanced by CC-4047. a…

Fig. 3 NK cells play important roles in inducing K562 apoptosis enhanced by CC-4047. a After three days in culture with CC-4047 or CC-5013, increased CD56bright NK cells and NKT cells (CD56+CD3+ cells) numbers were detected in PBMC from six tested donors. Plots show representative results. b Histograms of a representative experiment comparing regular PBMC and NK-depleted PBMC in the co-culture model. NK cells were depleted from PBMC and tested in the co-culture model with K562 cells as described in Materials and methods. Non-depleted regular PBMC from the same donor are shown on the left panel and NK-depleted PBMC on the right. For each double-peaked sample, the right peak indicates the apoptotic population of K562. The level of apoptosis is listed above each histogram. This experiment was repeated three times using PBMC from different donors. c Comparison of CC-4047 effects on regular non-depleted PBMC (PBMC), NK-depleted PBMC (PBMC-NK), and purified NK cells (NK). NK cells were isolated from PBMC and treated with IL-2 followed by DMSO or 1 μM CC-4047 as described in Materials and methods. As a control, regular PBMC and NK-depleted PBMC from the same donor were treated under the same conditions. Data show representative results of four independent experiments with PBMC from different donors. d Effect of 1 μM CC-4047 on purified NK-mediated K562 apoptosis at different NK-to-target ratios. Different effector-to-target ratios were tested for isolated NK-mediated K562 apoptosis. Ratio of 1:1 matches the NK cell-to-K562 ratio in non-depleted K562/PBMC co-culture. Data in c and d show representative results of four independent experiments with PBMC from different donors
Fig. 4

Fig. 4

CC-4047 and CC-5013 show no…

Fig. 4

CC-4047 and CC-5013 show no additive effect in combination with Rituximab and complement…

Fig. 4 CC-4047 and CC-5013 show no additive effect in combination with Rituximab and complement in Raji mono-cell culture but enhance Raji apoptosis in co-culture model as single agent or in combination with Rituximab. a Raji cells were cultured with Rituximab (10 μg/ml) and increasing concentrations of complement in the absence or presence of CC-4047 and CC-5013. Rituximab plus complement inhibited cell proliferation in a dose dependent manner. CC-4047 and CC-5013 had a very modest effect on Raji cell proliferation and showed no additive effect with Rituximab plus complement in this mono-cell culture assay. b Enhancement of PBMC-mediated Raji apoptosis by CC-4047 and CC-5013 is dose-dependent. PBMC were treated with CC-4047 or CC-5013 for 72 h prior to co-culture. These PBMC were then co-cultured with pre-labeled Raji cells at 30:1 or 15:1 ratio for 3 h, followed by labeling with AnnexinV-APC and analysis with FACSArray Bioanalyzer. Each data point represents the average of triplicate results. Shown is the result from 30:1 ratio. Similar trend of apoptosis induction was obtained with 15:1 ratio (data not shown). c Combination studies of Rituximab and CC-4047 and CC-5013 in Raji/PBMC co-culture model. Raji cells were treated with or without various doses of Rituximab for 20 min. PBMC were treated with CC-4047 (10 μM) and CC-5013 (10 μM) for 72 h prior to the co-culture with Raji cells. Each data point represents the average of triplicate results (* Synergistic and ♣ additive as determined by fractional product method.)
Fig. 5

Fig. 5

CC-4047 and CC-5013 enhance PC-3…

Fig. 5

CC-4047 and CC-5013 enhance PC-3 cell apoptosis in co-culture model, in the presence…

Fig. 5 CC-4047 and CC-5013 enhance PC-3 cell apoptosis in co-culture model, in the presence or absence of Docetaxel pretreatment. a Enhancement of PBMC-mediated apoptosis by CC-4047 and CC-5013 is dose-dependent. PBMC were treated with CC-4047 or CC-5013 for 72 h. These PBMC were then co-cultured with pre-labeled PC-3 cells at 10:1 or 5:1 ratio for 18 h, followed by labeling with AnnexinV-APC and analysis with FACSArray Bioanalyzer. Each data point represents the average of triplicate results. Shown above is the result from 10:1 ratio. A similar dose response was obtained with the 5:1 ratio. Combination studies of Docetaxel and CC-4047 (b) or CC-5013 (c) in PC-3/PBMC co-culture model. PKH26 pre-labeled PC-3 cells were treated with or without various doses of Docetaxel for 6 h. PBMC were treated with CC-4047 or CC-5013 at various doses for 72 h prior to co-culture with PC-3 cells. Each data point represents the average of triplicate results (* Synergistic and ♣ additive as determined by fractional product method.)
See this image and copyright information in PMC

Similar articles

  • Properties of thalidomide and its analogues: implications for anticancer therapy. Teo SK. Teo SK. AAPS J. 2005 Mar 22;7(1):E14-9. doi: 10.1208/aapsj070103. AAPS J. 2005. PMID: 16146335 Free PMC article. Review.
  • Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. doi: 10.1158/1078-0432.CCR-05-0577. Clin Cancer Res. 2005. PMID: 16115943
  • lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. Wu L, et al. Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405. Clin Cancer Res. 2008. PMID: 18628480
  • Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Reddy N, et al. Br J Haematol. 2008 Jan;140(1):36-45. doi: 10.1111/j.1365-2141.2007.06841.x. Epub 2007 Nov 9. Br J Haematol. 2008. PMID: 17995965
  • Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. Gribben JG, Fowler N, Morschhauser F. Gribben JG, et al. J Clin Oncol. 2015 Sep 1;33(25):2803-11. doi: 10.1200/JCO.2014.59.5363. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195701 Free PMC article. Review.
See all similar articles

Cited by

  • Role of Immune Cells and Immunotherapy in Multiple Myeloma. Radhakrishnan V, Golla U, Kudva AK. Radhakrishnan V, et al. Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461. Life (Basel). 2024. PMID: 38672732 Free PMC article. Review.
  • Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. Warren KE, Vezina G, Krailo M, Springer L, Buxton A, Peer CJ, Figg WD, William-Hughes C, Kessel S, Fouladi M, Gajjar A, Bowers D. Warren KE, et al. J Clin Oncol. 2023 Jun 20;41(18):3374-3383. doi: 10.1200/JCO.22.01777. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126770 Free PMC article. Clinical Trial.
  • Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machaliński B. Kulig P, et al. Cancers (Basel). 2023 Feb 2;15(3):963. doi: 10.3390/cancers15030963. Cancers (Basel). 2023. PMID: 36765919 Free PMC article. Review.
  • Contribution of natural killer cells in innate immunity against colorectal cancer. Ghazvinian Z, Abdolahi S, Tokhanbigli S, Tarzemani S, Piccin A, Reza Zali M, Verdi J, Baghaei K. Ghazvinian Z, et al. Front Oncol. 2023 Jan 4;12:1077053. doi: 10.3389/fonc.2022.1077053. eCollection 2022. Front Oncol. 2023. PMID: 36686835 Free PMC article. Review.
  • Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties. Guo Y, Wang X, Wang Z, Mao L, Wang J, Peng L, Xu G. Guo Y, et al. Pharmaceuticals (Basel). 2022 Nov 27;15(12):1479. doi: 10.3390/ph15121479. Pharmaceuticals (Basel). 2022. PMID: 36558930 Free PMC article.
See all "Cited by" articles

References

    1. Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs. 2005;14:45–55. doi: 10.1517/13543784.14.1.45. - DOI - PubMed
    1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–322. doi: 10.1038/nrc1323. - DOI - PubMed
    1. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955–961. doi: 10.1038/sj.bjc.6601579. - DOI - PMC - PubMed
    1. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer. 2005;93:613–619. doi: 10.1038/sj.bjc.6602774. - DOI - PMC - PubMed
    1. Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D (2007) lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. Paper presented at 2007 ASCO annual meeting abstract 3023
Show all 38 references

MeSH terms

  • Antineoplastic Agents / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Apoptosis / drug effects* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cell Line, Tumor Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Coculture Techniques Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Drug Screening Assays, Antitumor / methods Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Flow Cytometry Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Humans Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Killer Cells, Natural / drug effects* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Killer Cells, Natural / immunology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Lenalidomide Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Leukocytes, Mononuclear / immunology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Lymphoma, Non-Hodgkin / immunology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Male Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Neoplasms / drug therapy Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Neoplasms / immunology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Prostatic Neoplasms / immunology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Thalidomide / analogs & derivatives* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Thalidomide / pharmacology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Substances

  • Antineoplastic Agents Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Thalidomide Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • pomalidomide Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Lenalidomide Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Related information

  • MedGen
  • PubChem Compound
  • PubChem Compound (MeSH Keyword)
  • PubChem Substance

LinkOut - more resources

  • Full Text Sources

    • Europe PubMed Central
    • PubMed Central
    • Springer

  • Other Literature Sources

    • The Lens - Patent Citations Database

  • Research Materials

    • NCI CPTC Antibody Characterization Program
Full text links [x] full text provider logo Springer Free PMC article [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To
  • Clipboard
  • Email
  • Save
  • My Bibliography
  • Collections
  • Citation Manager
[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Từ khóa » Cc-5013-nhl-008